Jointly provided by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc.
Release Date: December 12, 2023
Expiration Date: December 12, 2024
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this activity, participants should be able to:
PACE designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.5 contact hours.
PACE designates this continuing education activity for 4.5 contact hour(s) (0.45 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008073-9999-23-285-H01-P)
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty | Conflicts of Interest |
---|---|
Leslie Myers, PharmD, IgCP® Director of Clinical Services CureCare |
Has no relevant financial relationship(s) with ineligible companies to disclose. |
Ariel Marks, MD Assistant Professor of Neurology Boston University School of Medicine |
Has no relevant financial relationship(s) with ineligible companies to disclose |
Nikita Raje, MD, MSc, FACAAI Medical Director, Allergy-Immunology Clinic Medical Director, Immunology Division of Allergy Immunology Pulmonary and Sleep Medicine Children’s Mercy Kansas City Associate Professor of Internal Medicine and Pediatrics UMKC School of Medicine |
Has no relevant financial relationship(s) with ineligible companies to disclose |
Felicia Schaps, BSN, RN, CRNI, OCN, CNSC, IgCN® Capital Caring Hospice |
Has no relevant financial relationship(s) with ineligible companies to disclose. |
Joe DiStefano, RPh, IgCP®, CSP Vice President of Clinical Programs Nufactor |
Has no relevant financial relationship(s) with ineligible companies to disclose. |
Amy Clarke, MSN, RN, IgCN® VP, Clinical Nursing Practice Optum |
Advisor: Takeda, Grifols, Pfizer, Kedrion, Koru; Speaker: PTCA, PeerView |
Melody Bullock, MS, BSN, RN, BS, CRNI, IgCN® Clinical Science Liaison Innovative Health Sciences, LLC |
Employee: Innovative Health Sciences |
Amy Clarke, MSN, RN, IgCN® VP, Clinical Nursing Practice Optum |
Advisor: Takeda, Grifols, Pfizer, Kedrion, Koru; Speaker: PTCA, PeerView |
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in 4.5 hours. To successfully complete activities and receive CE credit, learners must follow these steps:
Pharmacists: Upon successfully completing the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
For additional information about the accreditation of this activity, please visit https://partnersed.com.